Table 2.
Study | Treatment type | Year | Number of trials | Patients | Therapy | OS (HR) | DFS (HR) |
---|---|---|---|---|---|---|---|
Tjokrowidjaja et al. [16] | Neoadjuvant + Adjuvant | 2013 | 21 | 3986 | Only abstract available | 0.86 | 0.77 |
(0.79 – 0.93) | (0.71 – 0.84) | ||||||
Tjokrowidjaja et al. [16] | Neoadjuvant | 2013 | 12 | 3047 | Only abstract available | 0.89 | 0.80 |
(0.81 – 0.98) | (0.73 – 0.88) | ||||||
Advanced bladder cancer- Meta-analysis Corporation [17] | Neoadjuvant | 2005 | 11 | 3005 | Platinum-based | 0.86 | 0.78 |
(0.77 – 0.95) | (0.77 –0.95) | ||||||
Winquist et al. [18] | Neoadjuvant | 2004 | 11^ | 2605 | Cisplatin-based | 0.90 | Insufficient data for analysis+ |
(0.82 – 0.99) | |||||||
Tjokrowidjaja et al. [16] | Adjuvant | 2013 | 9 | 939 | Only abstract available | 0.75 | 0.77 |
(0.63 – 0.90) | (0.71 – 0.84) | ||||||
Leow et al. [19] (Update of the meta-analysis below) |
Adjuvant | 2013 | 9# | 945 | Cisplatin-based | 0.77 | 0.66 |
(0.59 – 0.99) | (0.45 – 0.91) | ||||||
Advanced bladder cancer meta-analysis corporation [20] | Adjuvant | 2005 | 6* | 491 | Cisplatin-based | 0.75 | 0.68 |
(0.60 – 0.96) | (0.53 – 0.89) |
OS: Overall Survival. DFS: Disease Free Survival. HR: Hazard Ratio.
^11 trials had HR data for OS and only 8 trials had HR data for DFS.
+Less than half the number of patients assessed were available for DFS results, and therefore, no statistical pooling analysis was undertaken.
#9 trials had HR data for OS and only 7 trials had HR data for DFS.
*6 trials had HR data for OS and only 5 trials had HR data for DFS.